Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025
Fresenius Medical Care reported an 18% increase in operating income for 2024, reaching the upper end of its outlook range. The company achieved organic revenue growth of 4%, driven by Care Enablement and Care Delivery segments. U.S. same market treatment growth turned positive for the full year. The FME25 program delivered EUR 567 million in savings, surpassing the target, and the 2025 goal was raised to EUR 750 million. Reported net income grew by 8%, and the net financial leverage ratio improved from 3.2x to 2.9x. A 21% dividend increase is planned.
Fresenius Medical Care's strategic plan included exiting non-core assets, impacting revenue by EUR 306 million and operating income by EUR 288 million. The company reduced net financial debt by 9% to EUR 9.8 billion. Group revenue increased by 2% in Q4 2024 to EUR 5,085 million, with Care Enablement revenue growing by 11%. Operating income for Q4 decreased by 39%, but on an outlook base, it increased by 31%.
For 2025, Fresenius Medical Care expects revenue growth to be positive to a low-single digit percent rate and operating income to grow by a high-teens to high-twenties percent rate. The company treated 299,352 patients in 3,675 clinics worldwide as of December 31, 2024.
Fresenius Medical Care ha riportato un aumento del 18% dell'utile operativo per il 2024, raggiungendo il limite superiore della sua previsione. L'azienda ha ottenuto un aumento dei ricavi organici del 4%, sostenuto dai segmenti Care Enablement e Care Delivery. La crescita del trattamento nel mercato statunitense è diventata positiva per l'intero anno. Il programma FME25 ha generato risparmi per 567 milioni di euro, superando l'obiettivo, e il traguardo per il 2025 è stato alzato a 750 milioni di euro. L'utile netto riportato è cresciuto dell'8% e il rapporto di leva finanziaria netta è migliorato da 3,2x a 2,9x. È previsto un aumento del dividendo del 21%.
Il piano strategico di Fresenius Medical Care includeva l'uscita da attività non core, impattando i ricavi per 306 milioni di euro e l'utile operativo per 288 milioni di euro. L'azienda ha ridotto il debito finanziario netto del 9%, portandolo a 9,8 miliardi di euro. I ricavi del gruppo sono aumentati del 2% nel quarto trimestre del 2024, raggiungendo 5.085 milioni di euro, con i ricavi da Care Enablement in crescita dell'11%. L'utile operativo per il quarto trimestre è diminuito del 39%, ma su base prospettica è aumentato del 31%.
Per il 2025, Fresenius Medical Care si aspetta che la crescita dei ricavi sia positiva, con un tasso di aumento a una cifra bassa, e che l'utile operativo cresca tra il 15% e il 25%. L'azienda ha trattato 299.352 pazienti in 3.675 cliniche in tutto il mondo al 31 dicembre 2024.
Fresenius Medical Care reportó un aumento del 18% en el ingreso operativo para 2024, alcanzando el extremo superior de su rango de pronóstico. La compañía logró un crecimiento de ingresos orgánicos del 4%, impulsado por los segmentos de Habilitación de Cuidado y Entrega de Cuidado. El crecimiento del tratamiento en el mismo mercado de EE. UU. se volvió positivo para todo el año. El programa FME25 generó 567 millones de euros en ahorros, superando el objetivo, y la meta para 2025 se elevó a 750 millones de euros. El ingreso neto reportado creció un 8%, y el ratio de apalancamiento financiero neto mejoró de 3.2x a 2.9x. Se planea un aumento del dividendo del 21%.
El plan estratégico de Fresenius Medical Care incluyó la salida de activos no centrales, impactando los ingresos en 306 millones de euros y el ingreso operativo en 288 millones de euros. La compañía redujo la deuda financiera neta en un 9%, llevándola a 9.8 mil millones de euros. Los ingresos del grupo aumentaron un 2% en el cuarto trimestre de 2024, alcanzando 5,085 millones de euros, con ingresos de Habilitación de Cuidado creciendo un 11%. El ingreso operativo para el cuarto trimestre disminuyó un 39%, pero en base a perspectivas, aumentó un 31%.
Para 2025, Fresenius Medical Care espera que el crecimiento de ingresos sea positivo a un porcentaje de un solo dígito bajo y que el ingreso operativo crezca entre un 15% y un 25%. La compañía trató a 299,352 pacientes en 3,675 clínicas en todo el mundo al 31 de diciembre de 2024.
프레제니우스 메디컬 케어는 2024년 운영 수익이 18% 증가했다고 보고하며, 전망 범위의 상한에 도달했습니다. 이 회사는 케어 활성화 및 케어 제공 부문에 힘입어 4%의 유기적 수익 성장을 달성했습니다. 미국의 동종 시장 치료 성장은 연간 기준으로 긍정적으로 전환되었습니다. FME25 프로그램은 5억 6,700만 유로의 절감을 가져왔으며, 목표를 초과 달성했고, 2025년 목표는 7억 5천만 유로로 상향 조정되었습니다. 보고된 순이익은 8% 증가했으며, 순재무 레버리지 비율은 3.2배에서 2.9배로 개선되었습니다. 21%의 배당금 증가가 계획되어 있습니다.
프레제니우스 메디컬 케어의 전략 계획에는 비핵심 자산의 매각이 포함되어 있으며, 이는 수익에 3억 6백만 유로, 운영 수익에 2억 8천8백만 유로에 영향을 미쳤습니다. 이 회사는 순재무 부채를 9% 줄여 98억 유로로 감소시켰습니다. 그룹 수익은 2024년 4분기 동안 2% 증가하여 50억 8,500만 유로에 도달했으며, 케어 활성화 수익은 11% 증가했습니다. 4분기 운영 수익은 39% 감소했지만, 전망 기준으로는 31% 증가했습니다.
2025년을 위해 프레제니우스 메디컬 케어는 수익 성장이 긍정적이며 낮은 단일 숫자 비율로 예상하고, 운영 수익은 고수익에서 고수익의 비율로 증가할 것으로 예상하고 있습니다. 이 회사는 2024년 12월 31일 기준으로 전 세계 3,675개 클리닉에서 299,352명의 환자를 치료했습니다.
Fresenius Medical Care a annoncé une augmentation de 18% de son résultat d'exploitation pour 2024, atteignant la limite supérieure de ses prévisions. L'entreprise a réalisé une croissance organique des revenus de 4%, soutenue par les segments de la Facilitation des Soins et de la Livraison des Soins. La croissance des traitements sur le même marché aux États-Unis est devenue positive pour l'année entière. Le programme FME25 a permis d'économiser 567 millions d'euros, dépassant l'objectif, et l'objectif pour 2025 a été relevé à 750 millions d'euros. Le résultat net rapporté a augmenté de 8%, et le ratio d'endettement financier net s'est amélioré, passant de 3,2x à 2,9x. Une augmentation de 21% du dividende est prévue.
Le plan stratégique de Fresenius Medical Care incluait la sortie d'actifs non essentiels, impactant les revenus de 306 millions d'euros et le résultat d'exploitation de 288 millions d'euros. L'entreprise a réduit sa dette financière nette de 9% pour atteindre 9,8 milliards d'euros. Le chiffre d'affaires du groupe a augmenté de 2% au quatrième trimestre 2024, atteignant 5,085 millions d'euros, avec des revenus de la Facilitation des Soins en hausse de 11%. Le résultat d'exploitation pour le quatrième trimestre a diminué de 39%, mais sur une base de prévisions, il a augmenté de 31%.
Pour 2025, Fresenius Medical Care s'attend à une croissance des revenus positive à un taux à un chiffre bas et à une croissance du résultat d'exploitation entre 15% et 25%. L'entreprise a traité 299 352 patients dans 3 675 cliniques dans le monde au 31 décembre 2024.
Fresenius Medical Care berichtete von einem 18%igen Anstieg des Betriebsgewinns für 2024 und erreichte damit das obere Ende seiner Prognose. Das Unternehmen erzielte ein organisches Umsatzwachstum von 4%, angetrieben von den Segmenten Care Enablement und Care Delivery. Das Wachstum der Behandlung im gleichen Markt in den USA wurde für das gesamte Jahr positiv. Das FME25-Programm erzielte Einsparungen von 567 Millionen Euro, übertraf das Ziel und das Ziel für 2025 wurde auf 750 Millionen Euro angehoben. Der berichtete Nettogewinn wuchs um 8%, und das Verhältnis der Nettoverschuldung verbesserte sich von 3,2x auf 2,9x. Eine 21%ige Dividendensteigerung ist geplant.
Der strategische Plan von Fresenius Medical Care beinhaltete den Ausstieg aus nicht zum Kerngeschäft gehörenden Vermögenswerten, was die Einnahmen um 306 Millionen Euro und den Betriebsgewinn um 288 Millionen Euro beeinträchtigte. Das Unternehmen reduzierte die Nettoverschuldung um 9% auf 9,8 Milliarden Euro. Der Gruppenumsatz stieg im vierten Quartal 2024 um 2% auf 5.085 Millionen Euro, wobei der Umsatz aus Care Enablement um 11% wuchs. Der Betriebsgewinn für das vierte Quartal sank um 39%, stieg jedoch auf Basis der Prognose um 31%.
Für 2025 erwartet Fresenius Medical Care ein positives Umsatzwachstum im niedrigen einstelligen Prozentbereich und ein Betriebsgewinnwachstum im hohen Teenager- bis hohen Zwanziger-Prozentbereich. Das Unternehmen behandelte zum 31. Dezember 2024 insgesamt 299.352 Patienten in 3.675 Kliniken weltweit.
- 18% operating income growth in 2024
- 4% organic revenue growth
- FME25 savings of EUR 567 million
- 21% planned dividend increase
- Net financial leverage ratio reduced to 2.9x
- Revenue negatively impacted by EUR 306 million due to divestitures
- Operating income negatively impacted by EUR 288 million due to divestitures
Insights
Fresenius Medical Care's 2024 results reveal a successful execution of its strategic turnaround, with the company hitting the top end of its guidance by delivering 18% operating income growth on outlook basis. This performance signals a significant inflection point in the company's transformation journey.
The company's FME25 program has exceeded expectations, delivering €221 million in additional savings for 2024, ahead of the €200 million target. The accumulated savings of €567 million and the confidence to raise the 2025 target to €750 million (from €650 million) demonstrates management's ability to execute operational efficiencies more rapidly than initially projected. This acceleration suggests potential for margin expansion beyond current forecasts.
A critical turnaround milestone was achieved in the Care Delivery segment, where underlying U.S. same market treatment growth turned positive (+0.1%) for the full year and accelerated to +0.5% in Q4. This metric is particularly significant as it indicates stabilization in FMS's core patient base after several challenging years, potentially establishing a foundation for sustainable organic growth.
The Care Enablement segment demonstrated remarkable improvement, swinging from an operating loss of €67 million in 2023 to a €267 million profit in 2024. This dramatic turnaround, resulting in a margin improvement from -1.2% to 4.8%, validates management's strategic focus on this higher-margin business and suggests further upside potential as the company continues to optimize its product portfolio.
The company's disciplined capital allocation strategy is bearing fruit, with net debt reduced by 9% to €9.8 billion and the leverage ratio improving from 3.2x to 2.9x. This strengthened financial position provides greater flexibility for future investments while supporting the 21% dividend increase to €1.44 per share, signaling management's confidence in sustainable earnings growth.
Portfolio optimization efforts continued with the divestiture of operations across multiple markets, affecting approximately 33,800 dialysis patients and 8,200 employees. While these exits created a €288 million negative impact on reported operating income, they align with the company's strategy of focusing resources on core, higher-margin businesses.
The Q4 free cash flow increase of 25% to €599 million is particularly impressive given it was achieved without the benefit of the prior year's Tricare settlement. This improvement in underlying cash generation supports the company's deleveraging efforts and dividend growth.
Looking forward, FMS's 2025 guidance for high-teens to high-twenties percent earnings growth translates to an 11-12% operating margin, representing significant progress toward industry-competitive profitability levels. However, investors should monitor potential headwinds from volume-based procurement in China, which management noted as pressuring pricing despite supporting volume growth.
The transformation journey appears to be gaining momentum rather than plateauing, suggesting potential for continued operational improvements beyond the formal conclusion of the FME25 program. With two years of successful execution against their strategic plan, FMS is demonstrating a credible path to sustainable margin expansion and earnings growth.
- Organic revenue growth1 of
4% driven by Care Enablement and Care Delivery - Underlying
U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year - Accumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to
EUR 750 million - With
18% operating income2 growth top end of the 2024 outlook range reached - Reported operating income grew by
2% , reported net income3 by +8% - Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by
21% - High teens to high twenties percent earnings growth in 2025, translating into an 11 to
12% margin
BAD HOMBURG,
Key figures Q4 and FY 2024 | ||||||||
Q4 2024 | Q4 2023 | Growth | Growth | FY 2024 | FY 2023 | Growth | Growth | |
EUR m | EUR m | yoy | yoy, cc | EUR m | EUR m | yoy | yoy, cc | |
Revenue | 5,085 | 4,988 | +2 % | +2 % | 19,336 | 19,454 | -1 % | 0 % |
on outlook base2 | 5,069 | 4,834 | +5 % | 19,454 | 19,049 | +2 % | ||
Operating income | 259 | 428 | -39 % | -39 % | 1,392 | 1,369 | +2 % | +3 % |
on outlook base2 | 489 | 373 | +31 % | 1,812 | 1,540 | +18 % | ||
Net income3 | 67 | 188 | -64 % | -62 % | 538 | 499 | +8 % | +9 % |
on outlook base2 | 266 | 154 | +73 % | 912 | 644 | +42 % | ||
Basic EPS (EUR) | 0.23 | 0.64 | -64 % | -62 % | 1.83 | 1.70 | +8 % | +9 % |
on outlook base2 | 0.91 | 0.52 | +73 % | 3.11 | 2.19 | +42 % | ||
yoy = year-on-year, cc = at constant currency, EPS = earnings per share |
Execution against the strategic plan translates into strong financial performance and further momentum
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, successfully finished year two of a three-year strategic turnaround and transformation plan.
Operational efficiency: In 2024, the FME25 transformation program accelerated its momentum, delivering
Portfolio Optimization: Fresenius Medical Care continues the execution of its portfolio optimization plan to exit non-core and dilutive assets. During 2024, the exit of clinic operations in multiple markets were announced and, except for
Capital Allocation: During 2024, Fresenius Medical Care strictly followed its disciplined financial policy. An increase of
Revenue development driven by robust organic growth1
In the fourth quarter 2024, Group revenue increased by
Care Delivery revenue decreased by
In Care Delivery
In Care Delivery International, revenue decreased by
Care Enablement revenue grew by
Within Inter-segment eliminations, revenue for products transferred between the operating segments at fair market value increased by
In the full year 2024, Group revenue decreased by
Strong operating income growth supported by both segments
In the fourth quarter 2024, Group operating income decreased by
Operating income in Care Delivery decreased by
Operating income in Care Enablement significantly increased to
Operating income for Corporate amounted to
In the full year 2024, Group operating income increased by
Net income3 in the fourth quarter 2024 decreased by
In the full year 2024, net income3 increased by
Basic earnings per share (EPS) decreased by
In the full year 2024, EPS increased by
Lower net financial debt and improved net leverage ratio driven by robust cash flow development
Fresenius Medical Care improved operating cash flow by
In the full year 2024, operating cashflow decreased by
Free cash flow5 increased by
Total net debt and lease liabilities were further reduced to
Patients, clinics and employees
As of December 31, 2024, Fresenius Medical Care treated 299,352 patients in 3,675 dialysis clinics worldwide and had 111,513 employees (headcount) globally, compared to 119,845 employees as of December 31, 2023.
Outlook 2025
In 2025, Fresenius Medical Care expects revenue growth to be positive to a low-single digit percent rate compared to prior year.
The Company expects operating income to grow by a high-teens to high-twenties percent rate compared to prior year.
The expected growth rates for 2025 are at constant currency, excluding special items2 in operating income. The 2024 basis for the revenue outlook is
Press conference
Fresenius Medical Care will host a virtual press conference to discuss the results of the fourth quarter and the full year 2024 today, February 25, 2024, at 10:00 a.m. CET / 4:00 a.m. EST. The press conference will be webcasted in the "Media" section (Link: Events | Fresenius Medical Care). A replay will be available shortly after the conference.
Investor conference call
Fresenius Medical Care will host a conference call for analysts and investors to discuss the results of the fourth quarter and the full year 2024 today, February 25, 2025, at 2:00 p.m. CET / 8:00 a.m. ET. Details are available on the Fresenius Medical Care website in the "Investors" section. A replay and a transcript will be available shortly after the call.
Please refer to our statement of earnings included at the end of this news and to the attachments as separate PDF files for a complete overview of the results of the fourth quarter and full year 2024. Our 20-F disclosure provides more details.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
_____________________________ |
1 At constant currency, adjusted for certain reconciling items including revenues from acquisitions, closed or sold operations and differences in dialysis days |
2 Revenue and operating income outlook, as referred to in the 2024 outlook, are both at constant currency, excluding special items as well as the business impact from closed divestitures in 2023 and the settlement agreement with the |
3 Net income attributable to shareholders of Fresenius Medical Care AG |
4 The company transfers products between segments at fair market value. The associated internal revenues and expenses and all other consolidation of transactions are included within "Inter-segment eliminations". |
5 Net cash provided by / used in operating activities, after capital expenditures, before acquisitions/divestitures, investments, and dividends |
Statement of earnings | ||||
Three months ended December 31, | ||||
in € million, except share data | 2024 | 2023 | Change | Change |
Revenue | 5,085 | 4,988 | 1.9 % | 1.6 % |
Revenue (outlook base)1 | 5,069 | 4,834 | 4.9 % | |
Costs of revenue | 3,814 | 3,638 | 4.8 % | 4.5 % |
Selling, general and administrative expense | 840 | 845 | -0.7 % | -0.8 % |
Research and development expense | 50 | 66 | -24.1 % | -24.3 % |
Income from equity method investees | (32) | (23) | 37.6 % | 37.6 % |
Other operating income | (228) | (257) | -11.5 % | -11.3 % |
Other operating expense | 382 | 291 | 30.9 % | 29.3 % |
Operating income | 259 | 428 | -39.5 % | -38.7 % |
Operating income (outlook base)1 | 489 | 373 | 31.0 % | |
Interest expense, net | 80 | 85 | -5.7 % | -6.4 % |
Income before taxes | 179 | 343 | -47.8 % | -46.6 % |
Income tax expense | 61 | 86 | -29.4 % | -28.6 % |
Net income | 118 | 257 | -54.0 % | -52.7 % |
Net income attributable to noncontrolling interests | 51 | 69 | -25.4 % | -25.9 % |
Net income2 | 67 | 188 | -64.4 % | -62.5 % |
Net income2 (outlook base)1 | 266 | 154 | 72.9 % | |
Weighted average number of shares | 293,413,449 | 293,413,449 | ||
Basic earnings per share | -64.4 % | -62.5 % | ||
Basic earnings per share (outlook base)1 | 72.9 % | |||
In percent of revenue | ||||
Operating income margin | 5.1 % | 8.6 % | ||
Operating income margin (outlook base)1 | 9.6 % | 7.7 % | ||
1 Outlook base as referred to the 2024 outlook, presented at constant currency, excluding special items, business | ||||
2 Attributable to shareholders of FME AG | ||||
Statement of earnings | |||||
Twelve months ended December 31, | |||||
in € million, except share data | 2024 | 2023 | Change | Change | |
Revenue | 19,336 | 19,454 | -0.6 % | 0.0 % | |
Revenue (outlook base)1 | 19,454 | 19,049 | 2.1 % | ||
Costs of revenue | 14,579 | 14,529 | 0.3 % | 1.0 % | |
Selling, general and administrative expense | 3,143 | 3,196 | -1.7 % | -1.2 % | |
Research and development expense | 183 | 232 | -20.9 % | -20.9 % | |
Income from equity method investees | (135) | (122) | 10.7 % | 10.7 % | |
Other operating income | (760) | (515) | 47.5 % | 47.8 % | |
Other operating expense | 934 | 765 | 22.1 % | 22.5 % | |
Operating income | 1,392 | 1,369 | 1.7 % | 2.6 % | |
Operating income (outlook base)1 | 1,812 | 1,540 | 17.6 % | ||
Interest expense, net | 335 | 336 | -0.3 % | -0.2 % | |
Income before taxes | 1,057 | 1,033 | 2.3 % | 3.5 % | |
Income tax expense | 316 | 301 | 5.2 % | 6.3 % | |
Net income | 741 | 732 | 1.1 % | 2.3 % | |
Net income attributable to noncontrolling interests | 203 | 233 | -13.1 % | -12.8 % | |
Net income2 | 538 | 499 | 7.8 % | 9.4 % | |
Net income2 (outlook base)1 | 912 | 644 | 41.6 % | ||
Weighted average number of shares | 293,413,449 | 293,413,449 | |||
Basic earnings per share | 7.8 % | 9.4 % | |||
Basic earnings per share (outlook base)1 | 41.6 % | ||||
In percent of revenue | |||||
Operating income margin | 7.2 % | 7.0 % | |||
Operating income margin (outlook base)1 | 9.3 % | 8.1 % | |||
1 Outlook base as referred to the 2024 outlook, presented at constant currency, excluding special items, business | |||||
2 Attributable to shareholders ofFME AG | |||||
Reconciliation of non-IFRS financial measures to the most directly comparable IFRS Accounting | ||||
Three months ended | Twelve months ended | |||
in € million | 2024 | 2023 | 2024 | 2023 |
Operating performance (outlook base) | ||||
These items are excluded to ensure comparability of the figures presented | ||||
Revenue | 5,085 | 4,988 | 19,336 | 19,454 |
Divestitures1 | — | 37 | — | (214) |
Tricare settlement | — | (191) | — | (191) |
Revenue excl. 2023 divestitures and Tricare settlement | 5,085 | 4,834 | 19,336 | 19,049 |
Currency translation effects | (16) | — | 118 | — |
Revenue (outlook base) | 5,069 | 4,834 | 19,454 | 19,049 |
Operating income | 259 | 428 | 1,392 | 1,369 |
FME25 Program | 73 | 52 | 180 | 153 |
Legal Form Conversion Costs | 4 | 17 | 9 | 30 |
Legacy Portfolio Optimization2 | 146 | 57 | 288 | 204 |
Humacyte Remeasurements | 7 | 1 | (72) | (15) |
Sum of special items: | 230 | 127 | 405 | 372 |
Divestitures1 | — | (1) | — | (20) |
Tricare settlement | — | (181) | — | (181) |
Sum of special items, 2023 divestitures and Tricare settlement | 230 | (55) | 405 | 171 |
Operating income excl. special items, 2023 divestitures and Tricare | 489 | 373 | 1,797 | 1,540 |
Currency translation effects | 0 | — | 15 | — |
Operating income (outlook base) | 489 | 373 | 1,812 | 1,540 |
Net income3 | 67 | 188 | 538 | 499 |
FME25 Program | 53 | 37 | 130 | 109 |
Legal Form Conversion Costs | 3 | 12 | 7 | 21 |
Legacy Portfolio Optimization2 | 138 | 21 | 282 | 138 |
Humacyte Remeasurements | 5 | 1 | (54) | (11) |
Sum of special items: | 199 | 71 | 365 | 257 |
Divestitures1 | — | 5 | — | (2) |
Tricare settlement | — | (110) | — | (110) |
Sum of special items, 2023 divestitures and Tricare settlement | 199 | (34) | 365 | 145 |
Net income3 excl. special items, 2023 divestitures and Tricare settlement | 266 | 154 | 903 | 644 |
Currency translation effects | 0 | — | 9 | — |
Net income3 (outlook base) | 266 | 154 | 912 | 644 |
1 Business impacts from closed divestitures in 2023 | ||||
2 2024: mainly comprise gains and losses from divestitures, impairment losses resulting from the measurement of assets held for sale | ||||
3 Attributable to shareholders of FME AG | ||||
Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-delivers-18-earnings-growth-in-2024-and-continues-the-acceleration-momentum-into-2025-302384002.html
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
What was the earnings growth for FMS in 2024?
How did the FME25 program perform in 2024?
What is the planned dividend increase for FMS?
How did divestitures affect FMS's financials in 2024?
What is the outlook for FMS in 2025?
What was the net financial leverage ratio for FMS at the end of 2024?
